started · updated
Proximal Ventures raises $27.5 million to fund AI in drug development
Sahir Raoof, a former SignalFire investor and healthcare executive, has launched Proximal Ventures with a $27.5 million debut fund. The venture capital firm aims to invest in pre-seed and seed-stage startups that utilize artificial intelligence to transform the tools, infrastructure, and services supporting drug development.
Raoof noted that pharmaceutical companies have traditionally been buyers of services rather than software, often outsourcing tasks such as molecular compound synthesis, manufacturing scale-up, and clinical trial data analysis. He believes AI can automate these service-oriented processes, allowing startups to capture significant pharmaceutical industry spending by delivering results faster and at a lower cost.
The fund plans to provide checks ranging from $500,000 to $1.5 million. Proximal Ventures has already supported six startups, including ChronicleBio, a company co-founded by former OpenAI executive Fidji Simo that uses AI to analyze biological and medical data for chronic disease research.
Entities
ChronicleBio · Fidji Simo · Proximal Ventures · Sahir Raoof · SignalFire